复方阿嗪米特肠溶片联合雷贝拉唑和莫沙必利治疗胆汁反流性胃炎临床观察  

Compound azintamide combined rabeprazole and mosapride triple therapy for bile reflux gastritis

作　　者：李雪梅[1] 

机构地区：[1]保定市第一中心医院消化内二科,河北保定071000

出　　处：《中南药学》2014年第3期281-283,共3页Central South Pharmacy

摘　　要：目的观察复方阿嗪米特肠溶片、质子泵抑制剂(PPI:雷贝拉唑肠溶片)及胃肠动力药(莫沙必利分散片)联合治疗胆汁反流性胃炎的疗效。方法 120例胆汁反流性胃炎患者采用随机方法分为2组,治疗组60例,给予雷贝拉唑肠溶片、莫沙必利分散片及复方阿嗪米特肠溶片联合治疗;对照组60例,应用雷贝拉唑肠溶片及莫沙必利分散片治疗。分别观察2组患者临床效果和胃镜效果。结果治疗组临床有效率达到93.3%,对照组有效率为81.7%,治疗组疗效显著优于对照组(P<0.05);且在改善饱胀症状上差异有统计学意义(P<0.01)。胃镜观察显示,治疗组胃镜观察总有效率为88.3%,与对照组比较差异有统计学意义(P<0.05),有效改善胆汁反流征象。结论胆汁反流性胃炎患者加用复方阿嗪米特肠溶片比单纯应用雷贝拉唑肠溶片和莫沙必利分散片治疗疗效更显著,值得大力推广。Objective To observe the effect of compound azintamide enteric-coated tablets, proton pump inhibitors（PPI： Rebela with enteric-coated tablets） and gastrointestinal prokinetic agents（mosapride dispersible tablets in the treatment of reflux gastritis patients） on bile reflux gastritis. Methods A total of 120 patients with reflux gastritis were randomly divided into 2 groups： 60 in the treatment group were given combination therapy of Rebela with enteric-coated tablets, mosapride dispersible tablet and compound azintamide enteric-coated tablets; the other 60 in the control group had Rebela with enteric-coated tablets and mosapride dispersible tablets. After the treatment, the clinical symptoms and gastroscope were observed in both groups. Results The treatment group showed a total effective rate of clinical symptoms 93.3%; that of the control group was 81.7%. The effect of the treatment group was better than the control group（P 0.05）. The effect of the treatment group as to symptoms of glutting was better than that of the control group（P 0.01）. Gastroscope observation showed in the 2 groups the defecation time had signifi-cant difference（P 0.05）, and the total effective rate of the treatment group in gastroscope was 88.3%. Conclusion Compound azintamide enteric-coated tablets（Mite） are better than proton pump inhibitors and mosapride dispersible tablets for chronic gastritis patients.

关 键 词：复方阿嗪米特肠溶片 质子泵抑制剂 胃肠动力药 反流性胃炎 雷贝拉唑 莫沙必利 

分 类 号：R969.4[医药卫生—药理学]